Moringa Acquisition Corp (MACAU)
| Previous close | 10.71 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 10.97 - 10.97 |
| 52-week range | 9.63 - 10.97 |
| Volume | |
| Avg. volume | 9 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.06 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireSilexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
Silexion’s first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients with non-resectable pancreatic cancer which harbors an oncogene believed to be a major driver of the cancer In combination with chemotherapy, Loder resulted in a median overall survival (OS) advantage of 9.3 months over chemotherapy alone (22.7 vs 13.4 months) Modi’in, Israel and New York, New York, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (Nasdaq: MACA) (“Mor
- GlobeNewswire
MORINGA ACQUISITION CORP ANNOUNCES CONTRIBUTION TO TRUST ACCOUNT IN CONNECTION WITH PROPOSED EXTENSION
New York, NY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa” or the “Company”) announced today that, in connection with its previously announced extraordinary general meeting in lieu of the 2023 annual general meeting of shareholders of the Company to be held at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time on August 16, 2023 (the “Extraordinary Meeting”) for the purpose of considering and voting on, among other proposals, a proposal to extend the dat
